Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Cancer Biogenesis in Ribosomopathies.

Sulima SO, Kampen KR, De Keersmaecker K.

Cells. 2019 Mar 11;8(3). pii: E229. doi: 10.3390/cells8030229. Review.

2.

Correction: The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Fancello L, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K.

Leukemia. 2019 Mar 8. doi: 10.1038/s41375-019-0424-x. [Epub ahead of print]

PMID:
30850735
3.

Ribosomal Lesions Promote Oncogenic Mutagenesis.

Sulima SO, Kampen KR, Vereecke S, Pepe D, Fancello L, Verbeeck J, Dinman JD, De Keersmaecker K.

Cancer Res. 2019 Jan 15;79(2):320-327. doi: 10.1158/0008-5472.CAN-18-1987. Epub 2018 Nov 27.

PMID:
30482776
4.

Rise of the specialized onco-ribosomes.

Kampen KR, Sulima SO, De Keersmaecker K.

Oncotarget. 2018 Oct 16;9(81):35205-35206. doi: 10.18632/oncotarget.26231. eCollection 2018 Oct 16. No abstract available.

5.

VEGFC Antibody Therapy Drives Differentiation of AML.

Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ESJM.

Cancer Res. 2018 Oct 15;78(20):5940-5948. doi: 10.1158/0008-5472.CAN-18-0250. Epub 2018 Sep 5.

PMID:
30185550
6.

The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.

Kampen KR, Sulima SO, Verbelen B, Girardi T, Vereecke S, Rinaldi G, Verbeeck J, Op de Beeck J, Uyttebroeck A, Meijerink JPP, Moorman AV, Harrison CJ, Spincemaille P, Cools J, Cassiman D, Fendt SM, Vermeersch P, De Keersmaecker K.

Leukemia. 2019 Feb;33(2):319-332. doi: 10.1038/s41375-018-0176-z. Epub 2018 Jun 21. Erratum in: Leukemia. 2019 Mar 8;:.

7.

The T-cell leukemia-associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.

Girardi T, Vereecke S, Sulima SO, Khan Y, Fancello L, Briggs JW, Schwab C, de Beeck JO, Verbeeck J, Royaert J, Geerdens E, Vicente C, Bornschein S, Harrison CJ, Meijerink JP, Cools J, Dinman JD, Kampen KR, De Keersmaecker K.

Leukemia. 2018 Mar;32(3):809-819. doi: 10.1038/leu.2017.225. Epub 2017 Jul 24.

8.

The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types.

Fancello L, Kampen KR, Hofman IJ, Verbeeck J, De Keersmaecker K.

Oncotarget. 2017 Feb 28;8(9):14462-14478. doi: 10.18632/oncotarget.14895.

9.

Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.

Shirzad R, Shahrabi S, Ahmadzadeh A, Kampen KR, Shahjahani M, Saki N.

Clin Transl Oncol. 2016 Oct;18(10):957-71. doi: 10.1007/s12094-015-1477-6. Epub 2016 Jan 7. Review.

PMID:
26742939
10.

Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?

van der Sligte NE, Kampen KR, de Bont ES.

Cell Mol Life Sci. 2015 Oct;72(19):3589-98. doi: 10.1007/s00018-015-2019-7. Epub 2015 Aug 31.

11.

Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia.

van der Sligte NE, Kampen KR, ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Guryev V, van Leeuwen FN, Kornblau SM, de Bont ES.

Oncotarget. 2015 Jun 20;6(17):14970-81.

12.

Acute myeloid leukemia in the vascular niche.

Cogle CR, Bosse RC, Brewer T, Migdady Y, Shirzad R, Kampen KR, Saki N.

Cancer Lett. 2016 Oct 1;380(2):552-60. doi: 10.1016/j.canlet.2015.05.007. Epub 2015 May 8. Review.

PMID:
25963886
13.

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES.

Mol Cancer Res. 2015 Jun;13(6):982-92. doi: 10.1158/1541-7786.MCR-14-0660-T. Epub 2015 May 5.

14.

Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.

Sie M, den Dunnen WF, Lourens HJ, Meeuwsen-de Boer TG, Scherpen FJ, Zomerman WW, Kampen KR, Hoving EW, de Bont ES.

PLoS One. 2015 Mar 23;10(3):e0122555. doi: 10.1371/journal.pone.0122555. eCollection 2015.

15.

Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.

Kampen KR, Ter Elst A, Mahmud H, Scherpen FJ, Diks SH, Peppelenbosch MP, de Haas V, Guryev V, de Bont ES.

Leukemia. 2014 Mar;28(3):589-99. doi: 10.1038/leu.2013.342. Epub 2013 Nov 18.

PMID:
24240200
16.

Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.

Weidenaar AC, Ter Elst A, Kampen KR, Meeuwsen-de Boer T, Kamps WA, Schuringa JJ, de Bont ES.

Mol Cancer Res. 2013 Apr;11(4):339-48. doi: 10.1158/1541-7786.MCR-12-0113. Epub 2013 Feb 7.

17.

An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen.

Zhang J, Jex E, Feng T, Sivko GS, Baillie LW, Goldman S, Van Kampen KR, Tang DC.

Clin Vaccine Immunol. 2013 Jan;20(1):1-8. doi: 10.1128/CVI.00280-12. Epub 2012 Oct 24.

18.

Vascular endothelial growth factor signaling in acute myeloid leukemia.

Kampen KR, Ter Elst A, de Bont ES.

Cell Mol Life Sci. 2013 Apr;70(8):1307-17. doi: 10.1007/s00018-012-1085-3. Epub 2012 Jul 26. Review.

PMID:
22833169
19.

EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.

Sikkema AH, den Dunnen WF, Hulleman E, van Vuurden DG, Garcia-Manero G, Yang H, Scherpen FJ, Kampen KR, Hoving EW, Kamps WA, Diks SH, Peppelenbosch MP, de Bont ES.

Neuro Oncol. 2012 Sep;14(9):1125-35. doi: 10.1093/neuonc/nos130. Epub 2012 Jun 21.

20.

The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology.

Kampen KR.

Anticancer Drugs. 2012 Apr;23(4):347-54. doi: 10.1097/CAD.0b013e32835004ac. Review.

PMID:
22261741
21.

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling.

Weidenaar AC, ter Elst A, Kampen KR, Meeuwsen-de Boer TG, de Jonge HJ, Scherpen FJ, den Dunnen WF, Kamps WA, de Bont ES.

Br J Cancer. 2011 Dec 6;105(12):1856-63. doi: 10.1038/bjc.2011.460. Epub 2011 Nov 1.

22.

The discovery and early understanding of leukemia.

Kampen KR.

Leuk Res. 2012 Jan;36(1):6-13. doi: 10.1016/j.leukres.2011.09.028. Epub 2011 Oct 26. Review.

PMID:
22033191
23.

Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza.

Zhang J, Tarbet EB, Feng T, Shi Z, Van Kampen KR, Tang DC.

PLoS One. 2011;6(7):e22605. doi: 10.1371/journal.pone.0022605. Epub 2011 Jul 27.

24.

Membrane proteins: the key players of a cancer cell.

Kampen KR.

J Membr Biol. 2011 Jul;242(2):69-74. doi: 10.1007/s00232-011-9381-7. Epub 2011 Jul 6. Review.

PMID:
21732009
25.

Identification of new possible targets for leukemia treatment by kinase activity profiling.

Ter Elst A, Diks SH, Kampen KR, Hoogerbrugge PM, Ruijtenbeek R, Boender PJ, Sikkema AH, Scherpen FJ, Kamps WA, Peppelenbosch MP, de Bont ES.

Leuk Lymphoma. 2011 Jan;52(1):122-30. doi: 10.3109/10428194.2010.535181. Epub 2010 Dec 6.

PMID:
21133721
26.

Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia.

Kruizinga RC, de Jonge HJ, Kampen KR, Walenkamp AM, de Bont ES.

Pediatr Blood Cancer. 2011 Feb;56(2):294-7. doi: 10.1002/pbc.22783.

PMID:
20981743
27.

Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR.

Expert Rev Vaccines. 2009 Apr;8(4):469-81. doi: 10.1586/erv.09.1. Review.

28.

Toward the development of vectored vaccines in compliance with evolutionary medicine.

Tang DC, Van Kampen KR.

Expert Rev Vaccines. 2008 May;7(4):399-402. doi: 10.1586/14760584.7.4.399. Review. No abstract available.

PMID:
18444885
29.

Automated mass immunization of poultry: the prospect for nonreplicating human adenovirus-vectored in ovo vaccines.

Avakian AP, Poston RM, Kong FK, Van Kampen KR, Tang DC.

Expert Rev Vaccines. 2007 Jun;6(3):457-65. Review.

PMID:
17542759
30.

Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.

Kim HD, Tahara K, Maxwell JA, Lalonde R, Fukuiwa T, Fujihashi K, Van Kampen KR, Kong FK, Tang DC, Fukuchi K.

J Gene Med. 2007 Feb;9(2):88-98.

31.

Effect of a flue-curing process that reduces tobacco specific nitrosamines on the tumor promotion in SENCAR mice by cigarette smoke condensate.

Hayes JR, Meckley DR, Stavanja MS, Nelson PR, Van Kampen KR, Swauger JE.

Food Chem Toxicol. 2007 Mar;45(3):419-30. Epub 2006 Sep 14.

PMID:
17070977
32.

Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector.

Toro H, Tang DC, Suarez DL, Sylte MJ, Pfeiffer J, Van Kampen KR.

Vaccine. 2007 Apr 12;25(15):2886-91. Epub 2006 Sep 25.

33.

Viral vectors for malaria vaccine development.

Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F.

Vaccine. 2007 Mar 30;25(14):2567-74. Epub 2006 Aug 1. Review.

PMID:
16914237
34.

Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity.

Zhang J, Shi Z, Kong FK, Jex E, Huang Z, Watt JM, Van Kampen KR, Tang DC.

Infect Immun. 2006 Jun;74(6):3607-17.

35.

Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF.

Kim HD, Cao Y, Kong FK, Van Kampen KR, Lewis TL, Ma Z, Tang DC, Fukuchi K.

Vaccine. 2005 Apr 27;23(23):2977-86.

PMID:
15811643
36.

A differential proteome in tumors suppressed by an adenovirus-based skin patch vaccine encoding human carcinoembryonic antigen.

Huang CM, Shi Z, DeSilva TS, Yamamoto M, Van Kampen KR, Elmets CA, Tang DC.

Proteomics. 2005 Mar;5(4):1013-23.

37.

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, Marks D, Elmets CA, Tang DC.

Vaccine. 2005 Jan 11;23(8):1029-36.

PMID:
15620476
38.

Prospective highlights of functional skin proteomics.

Huang CM, Elmets CA, van Kampen KR, Desilva TS, Barnes S, Kim H, Tang DC.

Mass Spectrom Rev. 2005 Sep-Oct;24(5):647-60. Review.

PMID:
15376279
39.

Identification of Bacillus anthracis proteins associated with germination and early outgrowth by proteomic profiling of anthrax spores.

Huang CM, Foster KW, DeSilva TS, Van Kampen KR, Elmets CA, Tang DC.

Proteomics. 2004 Sep;4(9):2653-61.

PMID:
15352240
40.
41.

A responsive, sensitive, and reproducible dermal tumor promotion assay for the comparative evaluation of cigarette smoke condensates.

Meckley D, Hayes JR, Van Kampen KR, Mosberg AT, Swauger JE.

Regul Toxicol Pharmacol. 2004 Apr;39(2):135-49.

PMID:
15041145
42.

Comparative proteomic profiling of murine skin.

Huang CM, Foster KW, DeSilva T, Zhang J, Shi Z, Yusuf N, Van Kampen KR, Elmets CA, Tang DC.

J Invest Dermatol. 2003 Jul;121(1):51-64.

43.

Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines.

Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, van Kampen KR, Elmets CA, Tang DC.

J Virol. 2001 Dec;75(23):11474-82.

44.

AdEasy system made easier by selecting the viral backbone plasmid preceding homologous recombination.

Zeng M, Smith SK, Siegel F, Shi Z, Van Kampen KR, Elmets CA, Tang DC.

Biotechniques. 2001 Aug;31(2):260-2. No abstract available.

45.

Recombinant vaccine technology in veterinary medicine.

Van Kampen KR.

Vet Clin North Am Small Anim Pract. 2001 May;31(3):535-8, vii. Review.

PMID:
11446102
46.

Immunotherapy and cytokines.

Van Kampen KR.

Semin Vet Med Surg (Small Anim). 1997 Aug;12(3):186-92. Review.

PMID:
9283244
47.

Intratumoral bcg cell-wall preparation therapy and surgery in bovine ocular carcinoma.

Kleinschuster SJ, Bier J, Rapp HJ, Smart RA, Van Kampen KR, Walters JL.

Head Neck Surg. 1983 May-Jun;5(5):401-9. No abstract available.

PMID:
6874364
48.

Immunoprophylaxis of an ocular solid malignant tumor in cattle.

Kleinschuster SJ, Rapp HJ, Bier J, Muscoplat CC, Smart RA, Van Kampen KR.

J Natl Cancer Inst. 1983 Apr;70(4):771-6.

PMID:
6572763
49.

Relationship between ingestion of the locoweed Oxytropis sericea and congestive right-sided heart failure in cattle.

James LF, Hartley WF, Van Kampen KR, Nielsen D.

Am J Vet Res. 1983 Feb;44(2):254-9.

PMID:
6830014
50.

Syndromes of astragalus poisoning in livestock.

James LF, Hartley WJ, Van Kampen KR.

J Am Vet Med Assoc. 1981 Jan 15;178(2):146-50. No abstract available.

PMID:
7204239

Supplemental Content

Loading ...
Support Center